Education
About Us
Working with TipRanks
Follow Us
Ventyx Biosciences (VTYX)
NASDAQ:VTYX
VTYX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.22 - $5.96
Previous CloseN/A
Volume4.54M
Average Volume (3M)843.42K
Market Cap
$86.78M
Enterprise Value-$51.45M
Total Cash (Recent Filing)$27.26M
Total Debt (Recent Filing)$10.79M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
May 08, 2025EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.99
Shares Outstanding71,130,050
10 Day Avg. Volume698,594
30 Day Avg. Volume843,417
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.35
Forecast
1Y Price Target
$15.33Price Target Upside1146.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Ventyx Biosciences News
PremiumCompany Announcements
Ventyx Biosciences Reports 2024 Financial Results and Progress
PremiumCompany Announcements
Ventyx Biosciences Unveils 2025 Pipeline and Clinical Updates
PremiumCompany Announcements
Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsNo dose-limiting toxicities were observed in the Phase 1 trials of VTX3232, indicating a favorable safety profile for further clinical development.
Financial ResourcesVentyx Biosciences has sufficient financial resources, with $252.9 million in cash and marketable securities expected to fund operations into at least the second half of 2026.
Pipeline DevelopmentThe Phase 2a study for VTX3232 in early Parkinson’s disease and the separate Phase 2 study for obesity with cardiovascular risk factors demonstrate Ventyx's commitment to advancing its NLRP3 inhibitor pipeline.
Bears Say
Investor SentimentThe short interest in Ventyx Biosciences is 11.2% of the float, which might indicate some investor skepticism or expectation of stock price decline.
Market CompetitionThese programs are viewed as high-risk/high-reward given the competitive nature of obesity and that historically, no studies have been positive in PD in late-stage development.
Stock PerformanceShares are down significantly as investors are in 'wait and see' mode on the company's NLRP3 franchise.
---
Ownership Overview
27.12% Insiders
9.80% Mutual Funds
23.49% Other Institutional Investors
30.87% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VTYX FAQ
What was Ventyx Biosciences’s price range in the past 12 months?
Ventyx Biosciences lowest stock price was $1.22 and its highest was $5.96 in the past 12 months.
What is Ventyx Biosciences’s market cap?
Ventyx Biosciences’s market cap is $86.78M.
When is Ventyx Biosciences’s upcoming earnings report date?
Ventyx Biosciences’s upcoming earnings report date is May 08, 2025 which is in 40 days.
How were Ventyx Biosciences’s earnings last quarter?
Ventyx Biosciences released its earnings results on Feb 27, 2025. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.527 by $0.117.
Is Ventyx Biosciences overvalued?
According to Wall Street analysts Ventyx Biosciences’s price is currently Undervalued.
Does Ventyx Biosciences pay dividends?
Ventyx Biosciences does not currently pay dividends.
What is Ventyx Biosciences’s EPS estimate?
Ventyx Biosciences’s EPS estimate is -0.48.
How many shares outstanding does Ventyx Biosciences have?
Ventyx Biosciences has 71,130,050 shares outstanding.
What happened to Ventyx Biosciences’s price movement after its last earnings report?
Ventyx Biosciences reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.527. Following the earnings report the stock price went up 8.966%.
Which hedge fund is a major shareholder of Ventyx Biosciences?
Currently, no hedge funds are holding shares in VTYX
---
Ventyx Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.33 (1146.34% Upside)
$15.33 (1146.34% Upside)
Blogger Sentiment
Bearish
VTYX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 9.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $49.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 8.5%
Last 30 Days ▼ 8.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-79.18%
12-Months-Change
Fundamentals
Return on Equity
-54.27%
Trailing 12-Months
Asset Growth
-0.54%
Trailing 12-Months
Company Description
Ventyx Biosciences
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
---
VTYX Stock 12 Month Forecast
Average Price Target
$15.33
▲(1146.34% Upside)
Technical Analysis
Best Analysts Covering VTYX
1 Year
1 Year Success Rate
6/23 ratings generated profit
1 Year Average Return
-19.48%
reiterated a buy rating 29 days ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 26.09% of your transactions generating a profit, with an average return of -19.48% per trade.
---